--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About CRMD20260220P8
Pharmaceutical
CorMedix Inc., was incorporated in Delaware on July 28, 2006. The Company is a biopharmaceutical company focused on the development and commercialization of therapeutic products for the prevention and treatment of life-threatening diseases and conditions. The company's main focus is the commercialization of its lead product, DefenCath, in the United States. The company has licensed the development and commercialization of DefenCath worldwide. The name DefenCath is an American proprietary name approved by the U.S. Food and Drug Administration (FDA).
